Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 7 | 2025 | 265 | 1.520 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 69 | 1.380 |
Why?
|
| Bayes Theorem | 10 | 2025 | 85 | 1.120 |
Why?
|
| Community-Based Participatory Research | 2 | 2025 | 122 | 0.820 |
Why?
|
| Ohio | 8 | 2025 | 64 | 0.820 |
Why?
|
| Decision Making | 1 | 2023 | 203 | 0.670 |
Why?
|
| Humans | 49 | 2026 | 34474 | 0.660 |
Why?
|
| Patient Admission | 2 | 2019 | 59 | 0.610 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 47 | 0.610 |
Why?
|
| HIV Infections | 4 | 2025 | 429 | 0.610 |
Why?
|
| Adult | 23 | 2025 | 10015 | 0.580 |
Why?
|
| Research Design | 2 | 2023 | 337 | 0.580 |
Why?
|
| Population Surveillance | 1 | 2019 | 133 | 0.560 |
Why?
|
| Male | 35 | 2025 | 20697 | 0.530 |
Why?
|
| Female | 35 | 2025 | 21490 | 0.520 |
Why?
|
| Hepatitis C | 3 | 2025 | 45 | 0.480 |
Why?
|
| Pharmacies | 2 | 2026 | 17 | 0.470 |
Why?
|
| Naloxone | 2 | 2026 | 33 | 0.470 |
Why?
|
| Narcotic Antagonists | 2 | 2026 | 47 | 0.460 |
Why?
|
| Adolescent | 12 | 2025 | 3799 | 0.460 |
Why?
|
| Data Collection | 1 | 2015 | 191 | 0.450 |
Why?
|
| Middle Aged | 21 | 2025 | 12703 | 0.440 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 439 | 0.440 |
Why?
|
| Young Adult | 11 | 2025 | 2825 | 0.410 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 140 | 0.380 |
Why?
|
| Rural Population | 2 | 2025 | 297 | 0.380 |
Why?
|
| Appalachian Region | 4 | 2025 | 20 | 0.380 |
Why?
|
| United States | 8 | 2026 | 4267 | 0.370 |
Why?
|
| Coronary Disease | 3 | 2022 | 239 | 0.340 |
Why?
|
| Hydrocortisone | 2 | 2021 | 61 | 0.320 |
Why?
|
| Length of Stay | 3 | 2019 | 335 | 0.310 |
Why?
|
| Blood Glucose | 3 | 2020 | 529 | 0.290 |
Why?
|
| Upper Extremity | 2 | 2019 | 68 | 0.290 |
Why?
|
| Telemedicine | 3 | 2025 | 120 | 0.280 |
Why?
|
| Aged | 15 | 2025 | 10998 | 0.270 |
Why?
|
| Bacterial Infections | 2 | 2018 | 51 | 0.270 |
Why?
|
| Homosexuality, Male | 2 | 2025 | 105 | 0.260 |
Why?
|
| Prevalence | 4 | 2024 | 1034 | 0.250 |
Why?
|
| Nonprescription Drugs | 1 | 2026 | 24 | 0.240 |
Why?
|
| Stroke | 3 | 2022 | 700 | 0.240 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 502 | 0.240 |
Why?
|
| Licensure | 1 | 2025 | 7 | 0.230 |
Why?
|
| Peer Group | 1 | 2025 | 45 | 0.230 |
Why?
|
| Automobile Driving | 1 | 2025 | 26 | 0.230 |
Why?
|
| African Americans | 3 | 2021 | 1435 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 97 | 0.220 |
Why?
|
| Heroin | 1 | 2024 | 33 | 0.210 |
Why?
|
| Placenta | 1 | 2024 | 76 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 260 | 0.210 |
Why?
|
| Physicians | 1 | 2025 | 167 | 0.200 |
Why?
|
| Accidents, Traffic | 1 | 2025 | 196 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2024 | 138 | 0.190 |
Why?
|
| Age Factors | 6 | 2025 | 1261 | 0.190 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 48 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 923 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 10 | 0.180 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3812 | 0.170 |
Why?
|
| Prognosis | 3 | 2019 | 1603 | 0.160 |
Why?
|
| Child | 7 | 2020 | 2613 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 2461 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2020 | 15 | 0.160 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 7 | 0.160 |
Why?
|
| Acute Disease | 2 | 2018 | 276 | 0.160 |
Why?
|
| Allostasis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Adiposity | 1 | 2021 | 204 | 0.150 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2022 | 488 | 0.150 |
Why?
|
| Aldosterone | 1 | 2019 | 27 | 0.150 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 53 | 0.150 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 33 | 0.150 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 7 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2019 | 15 | 0.150 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.150 |
Why?
|
| Anaphylaxis | 1 | 2019 | 12 | 0.150 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.150 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 24 | 0.150 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 5 | 0.150 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 8 | 0.150 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 2 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 47 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2022 | 1910 | 0.140 |
Why?
|
| Muscular Diseases | 1 | 2018 | 25 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 58 | 0.140 |
Why?
|
| Child Abuse | 1 | 2019 | 28 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 4 | 0.140 |
Why?
|
| Foot | 1 | 2018 | 42 | 0.140 |
Why?
|
| Paresis | 1 | 2018 | 18 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 204 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 28 | 0.140 |
Why?
|
| Office Visits | 1 | 2019 | 73 | 0.140 |
Why?
|
| Fever | 1 | 2018 | 63 | 0.140 |
Why?
|
| Motor Neurons | 1 | 2018 | 65 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2019 | 1354 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2019 | 92 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 167 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 83 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 801 | 0.140 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2019 | 124 | 0.140 |
Why?
|
| Exercise Test | 1 | 2019 | 247 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2017 | 20 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 2018 | 183 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 15 | 0.130 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 2 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2019 | 188 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 22 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 46 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 189 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2022 | 837 | 0.120 |
Why?
|
| Depression | 1 | 2019 | 458 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 378 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 215 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 123 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 1607 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 2352 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 568 | 0.110 |
Why?
|
| Ribonucleases | 1 | 2012 | 7 | 0.100 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.100 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 6 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 1032 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 46 | 0.090 |
Why?
|
| Organogenesis | 1 | 2012 | 18 | 0.090 |
Why?
|
| Infant | 3 | 2019 | 1122 | 0.090 |
Why?
|
| Skin Tests | 1 | 2011 | 13 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2011 | 26 | 0.080 |
Why?
|
| Risk Factors | 4 | 2019 | 4136 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1209 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 922 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2012 | 320 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2019 | 116 | 0.070 |
Why?
|
| Electromyography | 2 | 2018 | 68 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 1118 | 0.070 |
Why?
|
| Hand Strength | 2 | 2018 | 106 | 0.070 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 42 | 0.070 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 46 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 703 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 707 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 583 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 81 | 0.060 |
Why?
|
| Animals | 4 | 2024 | 8544 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1288 | 0.060 |
Why?
|
| Tissue Adhesions | 1 | 2024 | 12 | 0.060 |
Why?
|
| Drug Users | 1 | 2024 | 15 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2024 | 54 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 4150 | 0.050 |
Why?
|
| Random Allocation | 1 | 2024 | 257 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 85 | 0.050 |
Why?
|
| Massachusetts | 1 | 2023 | 29 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 217 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 193 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 228 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2366 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2023 | 129 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 323 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 47 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 819 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 75 | 0.050 |
Why?
|
| Pregnancy | 1 | 2024 | 1069 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 194 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 187 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2021 | 94 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 67 | 0.040 |
Why?
|
| Adiponectin | 1 | 2021 | 111 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 48 | 0.040 |
Why?
|
| Saliva | 1 | 2020 | 41 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 1946 | 0.040 |
Why?
|
| North Carolina | 1 | 2024 | 1612 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 50 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 95 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 560 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2019 | 12 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 44 | 0.040 |
Why?
|
| Mice | 2 | 2018 | 2691 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3618 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 28 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 38 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 2 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 30 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 105 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 23 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 18 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 48 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 108 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 37 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 4 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 262 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 310 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 438 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 76 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 100 | 0.030 |
Why?
|
| Triage | 1 | 2019 | 76 | 0.030 |
Why?
|
| Poverty | 1 | 2019 | 118 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 122 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 71 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 270 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 245 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 318 | 0.030 |
Why?
|
| Mortality | 1 | 2019 | 127 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 214 | 0.030 |
Why?
|
| Action Potentials | 1 | 2018 | 220 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2017 | 34 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 803 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 934 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 51 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 540 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 19 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 123 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 730 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 633 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 369 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 330 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 207 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 352 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 834 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 251 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 212 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 596 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 378 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1176 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1244 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 755 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 515 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 14 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 118 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 281 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 56 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 780 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 67 | 0.020 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 3 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 362 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1506 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2011 | 4 | 0.020 |
Why?
|
| Poaceae | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 236 | 0.020 |
Why?
|
| Allergens | 1 | 2011 | 16 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 137 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 152 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 429 | 0.020 |
Why?
|